A Phase 1 interventional study of HSK3486 and Moxifloxacin Hydrochloride in Anesthesia; Adverse Effect and Cardiac Arrhythmia, sponsored by Haisco-USA Pharmaceuticals, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Haisco-USA Pharmaceuticals, Inc. (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Arrhythmias, Cardiac with a site in China — 21 open to participants now, 24 under way, none of them phase 3. Arrhythmias, Cardiac · China.
Among the 46 studies in Arrhythmias, Cardiac with a site in China, this one is the 23rd largest by enrollment of the 27 interventional ones that give a count, is one of 8 that started in 2024, is the only one in phase 1, and was the 32nd registered.
1,051 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.
Browse Arrhythmias, Cardiac studies →21 of the 46 studies in Arrhythmias, Cardiac with a site in China are open now. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 18–75
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Canada and 4 more countries
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–80
Chensheng Pan · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 167 Arrhythmias, Cardiac studies recruiting now, 118 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 1983; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is below the median of 100 across 517 interventional studies indexed under Arrhythmias, Cardiac.
Median enrollment 130 across the 27 interventional studies, 1,000 across the 19 observational. Of the 16 that completed or were terminated, 6 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Haisco-USA Pharmaceuticals, Inc., one of the names counted as Haisco Pharmaceutical Group Co., Ltd.. Under that name alone:
Haisco-USA Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
Haisco Pharmaceutical Group Co., Ltd. has 1 study filed under Arrhythmias, Cardiac — fewer than ten, so there is no comparison to draw.
5 of the studies in Arrhythmias, Cardiac with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05694273First Affiliated Hospital Xi'an Jiaotong UniversityAcute Cerebrovascular Events in Patients Undergoing Catheter Ablation | 2026-12-01 |
| NCT07390513Chinese Academy of Medical Sciences, Fuwai HospitalElectrophysiological Outcomes After Transcatheter Aortic Valve Replacement | 2026-12-31 |
| NCT07669493Hebei Medical University Fourth HospitalCardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study | 2027-01-01 |
| NCT06984731Affiliated Hospital of Nantong UniversityThe Safety and Efficacy of Radiofrequency Ablation After Left Atrial Appendage Occlusion. | 2027-06-01 |
| NCT07217067Novartis PharmaceuticalsA Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | 2027-09-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 46 studies in Arrhythmias, Cardiac with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization (QTc interval of the electrocardiogram, and to evaluate the safety and tolerability of a single IV bolus of HSK3486 in healthy subjects
This is a single-center, randomized, blinded (except moxifloxacin hydrochloride tablet), placebo and positive controlled study with a 6-sequence, three-period crossover design in healthy subjects. A blinded design is used for administration of HSK3486 and placebo, and an open-label design is used for moxifloxacin hydrochloride tablet.
Subjects meet the including criteria and none of exclusion criteria are randomized in equal proportion to one of 6 dosing sequences (see Table 2 for dosing sequences), and the study procedure consisted of 3 periods, with washout period of 5 days between periods.
Subjects are closely monitored on vital sign checking, 12-lead ECG, and Holter collection through out each treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Abnormal 12-lead at screening or baseline (any test abnormality), including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One time, 0.4 mg/kg, IV bolus administration for 30 (±5) seconds
Drug: HSK3486
One time, IV bolus administration for 30 (±5) seconds
Drug: Placebo
One time, 0.4 g oral administration with 240 mL of warm water on an empty stomach.
Drug: Moxifloxacin Hydrochloride
Study Drug
Also known as: Cipepofol
Positive Control
Negative Control
Change-from-baseline in QTc Interval
Corrected for HR using the individual QT correction method (QTcI) - ΔQTcI
Time frame: From the base line ECG (D-2) to end of the period, up to 24 hours post-dose
A total of 175 subjects were screened in this study, 112 subjects failed screening, 3 subjects did not complete all procedures or assessments for inclusion and exclusion criteria, 48 subjects were randomized, and all 48 subjects completed the study.
| Milestone | Sequence 1: C-B-A | Sequence 2: A-B-C | Sequence 3: B-C-A | Sequence 4: C-A-B | Sequence 5: A-C-B | Sequence 6: B-A-C |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Corrected for HR using the individual QT correction method (QTcI) - ΔQTcI
| ms | C (Study Drug) | B (Positive Control) | A (Placebo) |
|---|---|---|---|
| 30s post-dose | 2.1 (0.46 to 3.74) | 5.1 (2.96 to 7.29) | -0.1 (-1.70 to 1.41) |
| 1 min post-dose | 4.1 (2.07 to 6.12) | -4.4 (-6.46 to -2.42) | 0.0 (-1.89 to 1.96) |
| 2 min post-dose | -3.1 (-4.24 to -1.90) | -7.7 (-8.88 to -6.56) | -3.1 (-4.24 to -1.91) |
| 3 min post-dose | -0.1 (-1.24 to 0.97) | -4.4 (-5.51 to -3.33) | -0.9 (-2.02 to 0.15) |
| 5 min post-dose | 4.4 (3.33 to 5.46) | -3.0 (-4.05 to -1.93) | 0.4 (-0.70 to 1.41) |
| 8 min post-dose | 5.1 (3.97 to 6.23) | -1.3 (-2.42 to -0.19) | 1.0 (-0.13 to 2.11) |
| 10 min post-dose | 4.7 (3.51 to 5.82) | -2.9 (-4.06 to -1.78) | 0.8 (-0.30 to 1.99) |
| 15 min post-dose | 3.3 (2.33 to 4.26) | -3.7 (-4.63 to -2.72) | 0.6 (-0.33 to 1.59) |
| 30 min post-dose | 1.0 (0.16 to 1.82) | -1.6 (-2.40 to -0.76) | 0.4 (-0.38 to 1.25) |
| 1 h post-dose | -0.1 (-1.22 to 1.12) | 5.2 (4.06 to 6.38) | 0.5 (-0.62 to 1.70) |
| 2 h post-dose | 1.1 (-0.07 to 2.34) | 10.0 (8.80 to 11.20) | 1.3 (0.08 to 2.46) |
| 3h post-dose | 0.5 (-0.75 to 1.77) | 13.2 (11.99 to 14.50) | 0.9 (-0.38 to 2.11) |
| 4h post-dose | 2.6 (1.30 to 3.84) | 14.8 (13.55 to 16.09) | 3.0 (1.75 to 4.27) |
| 6h post-dose | -1.0 (-2.98 to 0.93) | 8.0 (6.10 to 9.97) | -0.9 (-2.86 to 1.03) |
| 8h post-dose | -1.7 (-3.58 to 0.17) | 7.4 (5.58 to 9.29) | 1.12 (-2.41 to 1.30) |
| 12h post-dose | -0.9 (-2.70 to 0.91) | 6.2 (4.36 to 7.95) | 0.8 (-1.03 to 2.55) |
| 24h post-dose | -0.7 (-2.18 to 0.72) | 7.3 (5.85 to 8.74) | 0.1 (-1.35 to 1.52) |
Collected over From Screen period ( day -21) to 7±1 day after the last dose. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HSK3486( Study Drug) | 0/48 (0%) | 0/48 (0%) | 3/48 (6.3%) |
| Placebo | 0/48 (0%) | 0/48 (0%) | 0/48 (0%) |
| Moxifloxacin Hydrochloride | 0/48 (0%) | 0/48 (0%) | 3/48 (6.3%) |
| Event | HSK3486( Study Drug) | Placebo | Moxifloxacin Hydrochloride |
|---|---|---|---|
| Neutrophil count decreasedInvestigations | 2/48 | 0/48 | 1/48 |
| Alanine aminotransferase increasedInvestigations | 1/48 | 0/48 | 0/48 |
| White blood cell counts decreasedInvestigations | 1/48 | 0/48 | 0/48 |
| NauseaGastrointestinal disorders | 0/48 | 0/48 | 1/48 |
| HeadacheNervous system disorders | 0/48 | 0/48 | 1/48 |
| Blood creatine phosphokinase increasedInvestigations | 0/48 | 0/48 | 1/48 |
| Blood thyroid stimulating hormone decreasedInvestigations | 0/48 | 0/48 | 1/48 |
| Age, Continuous(Years) | Sequence 1: C-B-A | Sequence 2: A-B-C | Sequence 3: B-C-A | Sequence 4: C-A-B | Sequence 5: A-C-B | Sequence 6: B-A-C | Total |
|---|---|---|---|---|---|---|---|
| Age (Years) | 34.3 ± 4.77 | 31.1 ± 4.94 | 30.9 ± 3.56 | 31.0 ± 5.76 | 31.6 ± 5.26 | 34.9 ± 5.00 | 32.3 ± 4.94 |
| Sex: Female, Male(Participants) | Sequence 1: C-B-A | Sequence 2: A-B-C | Sequence 3: B-C-A | Sequence 4: C-A-B | Sequence 5: A-C-B | Sequence 6: B-A-C | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 1 | 1 | 0 | 2 | 8 |
| Male | 6 | 6 | 7 | 7 | 8 | 6 | 40 |
| Race (NIH/OMB)(Participants) | Sequence 1: C-B-A | Sequence 2: A-B-C | Sequence 3: B-C-A | Sequence 4: C-A-B | Sequence 5: A-C-B | Sequence 6: B-A-C | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 8 | 8 | 8 | 8 | 8 | 48 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Baseline BMI(kg/m2) | Sequence 1: C-B-A | Sequence 2: A-B-C | Sequence 3: B-C-A | Sequence 4: C-A-B | Sequence 5: A-C-B | Sequence 6: B-A-C | Total |
|---|---|---|---|---|---|---|---|
| Mean | 22.74 ± 0.964 | 22.81 ± 2.017 | 22.88 ± 1.429 | 21.41 ± 0.777 | 23.58 ± 1.296 | 22.70 ± 1.9777 | 22.69 ± 1.546 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2024 to primary completion in May 2024, 1 month.
Results were first posted in Jan 2026, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ciprofol
Haisco-USA Pharmaceuticals, Inc. →